MGC Pharmaceuticals Limited (ASX:MXC) Stock Price & Quote Analysis

MXC Stock Overview

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide.

MXC fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Revenue is forecast to grow 41.95% per year

Risk Analysis

Earnings have declined by 16.4% per year over past 5 years

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$5M)

+ 1 more risk

My Notes

New

Notes are coming soon

MGC Pharmaceuticals Limited Competitors

Creso Pharma

ASX:CPH

AU$37.2m

Nyrada

ASX:NYR

AU$23.4m

Acrux

ASX:ACR

AU$21.2m

Rhinomed

ASX:RNO

AU$27.1m

Price History & Performance

Summary of all time highs, changes and price drops for MGC Pharmaceuticals
Historical stock prices
Current Share Price	AU$0.011
52 Week High	AU$0.032
52 Week Low	AU$0.009
Beta	1.28
1 Month Change	-8.33%
3 Month Change	-15.38%
1 Year Change	-65.63%
3 Year Change	-66.67%
5 Year Change	-89.00%
Change since IPO	-92.41%

Recent updates

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

Feb 21

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

Dec 30

Shareholder Returns

	MXC	AU Pharmaceuticals	AU Market
7D	10.0%	-3.6%	0.8%
1Y	-65.6%	-29.0%	2.2%

Return vs Industry: MXC underperformed the Australian Pharmaceuticals industry which returned -29% over the past year.

Return vs Market: MXC underperformed the Australian Market which returned 2.2% over the past year.

Price Volatility

Is MXC's price volatile compared to industry and market?
MXC volatility
MXC Average Weekly Movement	16.8%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	8.5%
10% most volatile stocks in AU Market	15.5%
10% least volatile stocks in AU Market	3.4%

Stable Share Price: MXC is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: MXC's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Roby Zomer	https://mgcpharma.com.au

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.

MGC Pharmaceuticals Limited Fundamentals Summary

How do MGC Pharmaceuticals's earnings and revenue compare to its market cap?
MXC fundamental statistics
Market Cap	AU$32.07m
Earnings (TTM)	-AU$20.35m
Revenue (TTM)	AU$4.73m

6.8x

P/S Ratio

-1.6x

P/E Ratio

Is MXC overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MXC income statement (TTM)
Revenue	AU$4.73m
Cost of Revenue	AU$4.17m
Gross Profit	AU$562.87k
Other Expenses	AU$20.91m
Earnings	-AU$20.35m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.007
Gross Margin	11.89%
Net Profit Margin	-430.00%
Debt/Equity Ratio	40.5%

How did MXC perform over the long term?

See historical performance and comparison

MXC Stock Overview

Rewards

Risk Analysis

MGC Pharmaceuticals Limited Competitors

ASX:CPH

AU$37.2m

ASX:NYR

AU$23.4m

ASX:ACR

AU$21.2m

ASX:RNO

AU$27.1m

Price History & Performance

Recent News & Updates

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Recent updates

MGC Pharmaceuticals Limited Announces Change of CFO

MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm

Less than half of directors are independent

MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director

MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial

Price target decreased to AU$0.04

Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support

MGC Pharmaceuticals Limited Provides an Update on Its Operations

MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

Mgc Pharmaceuticals Limited Announces Board Changes

Full year 2022 earnings: EPS and revenues miss analyst expectations

MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19

MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study

MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial)

Price target decreased to AU$0.07

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC

Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer

MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support

MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19

MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech

MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report

Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer

Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann

MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office

Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer

MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office

MGC Pharmaceuticals Limited Announces Executive Changes

MGC Pharmaceuticals (ASX:MXC) Has Debt But No Earnings; Should You Worry?

MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India

Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients

MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding

MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding

Auditors Have Doubts About MGC Pharmaceuticals (ASX:MXC)

Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Uk Import Permit Granted for Cannepil

Full year 2021 earnings released: AU$0.007 loss per share (vs AU$0.014 loss in FY 2020)

MGC Pharmaceuticals Limited Announces Successful Submission of Self-Nano Emulsifying Cannabinoids-Ionic Complex Concentrate Drug Delivery System

Mgc Pharmaceuticals Limited Announces Phase Iii Cimetra Clinical Trial Commences

MGC Pharmaceuticals Limited Announces Cannabis Derived Epilepsy Investigational Medicinal Product

Mgc Pharmaceuticals Ltd Provides Progress Report on Major Clinical Trial Programs Planned for 2021

MGC Pharmaceuticals Ltd Announces Further Results from the Phase II Clinical and Preclinical Studies on ArtemiC(TM)

Joint Company Secretary has left the company

MGC Pharmaceuticals Limited Revives Increased Initial Supply Agreement for ArtemiC

If You Had Bought MGC Pharmaceuticals (ASX:MXC) Shares A Year Ago You'd Have Earned 346% Returns

MGC Pharmaceuticals Ltd Signs Master Suppy and Distribution Agreement with Swiss PharmaCan AG for Artemic Rescue

MGC Pharmaceuticals Limited Announces New In-Vitro Cannabinoid Study on Glioblastoma Treatment

Swiss Pharmacan AG, and MGC Pharma Report on Successful Phase II Clinical Results For COVID-19 Treatment Candidate Based on its MyCell Technology

MGC Pharmaceuticals Ltd Appoints Nicole Godresse as Its New Global Chief Sales Officer

What Does MGC Pharmaceuticals' (ASX:MXC) CEO Pay Reveal?

MGC Pharmaceuticals Limited Announces ArtemiC Phase II Clinical Trial Results

MGC Pharmaceuticals Limited Appoints Narelle Warren as Joint Company Secretary, Effective 30 November 2020

MGC Pharmaceuticals Limited (ASX:MXC) completed the acquisition of Clinical assets of Medicinal Cannabis Clinic Pty Ltd.

MGC Pharma Progresses Successful Results from Cannabinoid Treatment of Glioblastoma Towards Clinical Trials

MGC Pharmaceuticals Limited Announces Completion of Phase Ii Clinical Trial on Covid-19 Patients

MGC Pharmaceuticals Limited Announces Affordable Cannabinoid Product Line